IGF1 and neoplasm: I consider combination therapy of first-generation SSAs with cabergoline in symptomatic patients with IGF-1(<1.5-2ULN) while on the maximum tolerated dose of SSA (usually 40 mg octreotide or 120 mg lanerotide monthly) for at least 6 months, regardless of residual tumor size.